Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Pres, Prod Dev & Med Aff & CMO | July 26, 2021 | July 29, 2021 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date July 26, 2021 · Filed July 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 689,078 |
Reported balance
After 2021-07-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-26 · Exercise / conversion · Acquired 40,000 · Balance 689,078 F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2023-02-10 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-26 · Exercise / conversion · Disposed 40,000 · Balance 0 F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 14,880 |
Reported balance
Holding disclosure · report date 2021-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,880 F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021.
F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2018 Filed Jul 4, 2018 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,500 | $21.20 | $477,000.00 |
DisclosureSEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.10 to $21.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,500 | $20.80 | $468,000.00 |
DisclosureSEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.65 to $21.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000115 · wf-form4_152789751433380.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 03, 2018 Filed May 4, 2018 23:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000071 · wf-form4_152547516260192.xml · derivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| May 03, 2018 Filed May 4, 2018 23:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 14,700 | $23.47 | $345,009.00 |
DisclosureSEC source: 0000939767-18-000071 · wf-form4_152547516260192.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.98 to $23.75. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| May 03, 2018 Filed May 4, 2018 23:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 7,800 | $22.36 | $174,408.00 |
DisclosureSEC source: 0000939767-18-000071 · wf-form4_152547516260192.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.95 to $22.90. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 03, 2018 Filed May 4, 2018 23:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000071 · wf-form4_152547516260192.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,008 shares of common stock acquired on April 30, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 06, 2018 Filed Apr 6, 2018 23:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 14,591 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-18-000042 · wf-form4_152305847475704.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,109 Underlying: Common Stock · 14,591 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 210,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| April 06, 2018 Filed Apr 6, 2018 23:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 14,591 | $7.18 | $104,763.38 |
DisclosureSEC source: 0000939767-18-000042 · wf-form4_152305847475704.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 3, 2018 01:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 7,293 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000939767-18-000034 · wf-form4_152003903149839.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,293 shares Expires 2019-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 7,293 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013. Read SEC document |
| March 01, 2018 Filed Mar 3, 2018 01:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 7,293 | $4.42 | $32,235.06 |
DisclosureSEC source: 0000939767-18-000034 · wf-form4_152003903149839.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2017 Filed Nov 18, 2017 00:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,609 | $24.75 | $64,572.75 |
DisclosureSEC source: 0000939767-17-000194 · wf-form4_151096601230005.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,396 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. F2 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000171 · wf-form4_150724744606566.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-10-02 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000171 · wf-form4_150724744606566.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,005 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 95,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 33,334 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 10 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 33,334 | $23.74 | $791,349.16 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.70 to $23.76. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 33,334 | $9.91 | $330,339.94 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 9 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,333 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 33,333 | $23.94 | $797,992.02 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.70 to $24.22. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 33,333 | $9.91 | $330,330.03 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 8 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 33,333 | $23.68 | $789,325.44 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.66 to $23.80. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 33,333 | $9.91 | $330,330.03 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2017 Filed May 17, 2017 01:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 12,501 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-17-000086 · wf-form4_149498353176730.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,499 Underlying: Common Stock · 12,501 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| May 15, 2017 Filed May 17, 2017 01:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 12,501 | $5.04 | $63,005.04 |
DisclosureSEC source: 0000939767-17-000086 · wf-form4_149498353176730.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2017. F2 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 89,910 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000073 · wf-form4_149385612111738.xml · derivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 89,910 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 1,900 | $23.31 | $44,289.00 |
DisclosureSEC source: 0000939767-17-000073 · wf-form4_149385612111738.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,504 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2017. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.24 to $23.37. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 88,010 | $23.00 | $2,024,230.00 |
DisclosureSEC source: 0000939767-17-000073 · wf-form4_149385612111738.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,404 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2017. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.23 to $23.21. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 89,910 | $9.91 | $891,008.10 |
DisclosureSEC source: 0000939767-17-000073 · wf-form4_149385612111738.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 2,361 shares of common stock acquired on April 28, 2017, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 10,090 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000063 · wf-form4_149255983275104.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,910 Underlying: Common Stock · 10,090 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 10,090 | $9.91 | $99,991.90 |
DisclosureSEC source: 0000939767-17-000063 · wf-form4_149255983275104.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2017. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 32,300 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-17-000038 · wf-form4_148979469607480.xml · derivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,700 Underlying: Common Stock · 32,300 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 210,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 17,707 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000939767-17-000038 · wf-form4_148979469607480.xml · derivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,293 Underlying: Common Stock · 17,707 shares Expires 2019-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,007 | $22.53 | $1,126,657.71 |
DisclosureSEC source: 0000939767-17-000038 · wf-form4_148979469607480.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,053 Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 32,300 | $7.18 | $231,914.00 |
DisclosureSEC source: 0000939767-17-000038 · wf-form4_148979469607480.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 17,707 | $4.42 | $78,264.94 |
DisclosureSEC source: 0000939767-17-000038 · wf-form4_148979469607480.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 01, 2016 Filed Dec 3, 2016 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0000939767-16-000285 · wf-form4_148072401067321.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2016-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 44,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 8, 2010. Read SEC document |
| December 01, 2016 Filed Dec 3, 2016 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,000 | $16.73 | $368,060.00 |
DisclosureSEC source: 0000939767-16-000285 · wf-form4_148072401067321.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,053 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2016. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.52 to $17.00. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| December 01, 2016 Filed Dec 3, 2016 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,000 | $8.99 | $197,780.00 |
DisclosureSEC source: 0000939767-16-000285 · wf-form4_148072401067321.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 09, 2016 Filed Nov 15, 2016 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0000939767-16-000273 · wf-form4_147917017722260.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2016-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 44,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 8, 2010. Read SEC document |
| November 09, 2016 Filed Nov 15, 2016 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,000 | $15.00 | $330,000.00 |
DisclosureSEC source: 0000939767-16-000273 · wf-form4_147917017722260.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,053 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016. Read SEC document |
| November 09, 2016 Filed Nov 15, 2016 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,000 | $8.99 | $197,780.00 |
DisclosureSEC source: 0000939767-16-000273 · wf-form4_147917017722260.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,612 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 120,000 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-16-000256 · wf-form4_147493327752966.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2024-09-21 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-16-000256 · wf-form4_147493327752966.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,441 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2017, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.